BEOVU Versus Eylea in the Treatment of Diabetic Macular Edema

Last updated: July 4, 2021
Sponsor: Benha University
Overall Status: Active - Recruiting

Phase

3

Condition

Macular Edema

Treatment

N/A

Clinical Study ID

NCT04955171
Hamaky15
  • Ages > 18
  • All Genders

Study Summary

Diabetic macular edema degeneration occur is a vision threatening condition. The investigators compare the efficacy of BEOVU and Eylea intravitreal treatment in the management

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diabetic macular edema

Exclusion

Exclusion Criteria:

  • other causes of macular edema
  • other macular diseases

Study Design

Total Participants: 60
Study Start date:
January 12, 2021
Estimated Completion Date:
April 30, 2022

Study Description

Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done. Procedure included randomized intravitreal injection of Brolucizumab(BEOVU®, Genentech, South Francisco, CA) and of aflibercept (Eylea;Regeneron, Tarrytown,NY)

Connect with a study center

  • INMC

    Abu Dhabi, 46266
    United Arab Emirates

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.